Lexicon Pharmaceuticals (NASDAQ: LXRX) could have its first commercial drug on the market before the end of 2016, and based on recent study results, it may soon have a drug on the market that can help keep type 1 diabetes in check. Both events could mean that meaningful sales for this company are right around the corner, so let’s take a closer look at what’s going on.